Anti-CGRP Drugs Reduce Migraine Days by 1-4 Per Month and Work Even When Other Drugs Fail
Anti-CGRP monoclonal antibodies and the gepant atogepant reduce migraine days by 0.7-3.8 per month and remain effective in patients who failed previous oral prophylactic drugs.
Quick Facts
What This Study Found
Anti-CGRP antibodies reduce migraine days by 0.7-3.8/month and atogepant by 0.7-2.4/month, with efficacy maintained in patients refractory to traditional oral prophylactics.
Key Numbers
How They Did This
Narrative review based on International Headache Society guidelines with additional meta-analyses of anti-CGRP monoclonal antibodies and gepants.
Why This Research Matters
Migraine affects over 1 billion people globally. Anti-CGRP drugs represent the first migraine-specific preventive therapy class and help patients who don't respond to older medications.
The Bigger Picture
The success of anti-CGRP drugs validates decades of neuropeptide research and demonstrates how understanding peptide signaling can lead to transformative treatments.
What This Study Doesn't Tell Us
Efficacy data from clinical trials may not fully reflect real-world effectiveness. Head-to-head comparisons between anti-CGRP agents are limited. Long-term safety data still accumulating. Cost remains a barrier for many patients.
Questions This Raises
- ?Which anti-CGRP drug should be tried first?
- ?Can anti-CGRP drugs be combined with traditional prophylactics for refractory migraine?
- ?Are there biomarkers that predict response to anti-CGRP therapy?
Trust & Context
- Key Stat:
- Up to 3.8 fewer migraine days/month Fremanezumab showed the largest reduction; all anti-CGRP drugs effective even after traditional drug failure
- Evidence Grade:
- Review based on international guidelines and meta-analyses of randomized controlled trials. High-quality evidence.
- Study Age:
- Published in 2025, reflecting current International Headache Society guidelines.
- Original Title:
- Drugs for Migraine Prophylaxis.
- Published In:
- Deutsches Arzteblatt international (2026)
- Authors:
- Diener, Hans Christoph, Grans, Julia, Reuter, Uwe(9)
- Database ID:
- RPEP-15109
Evidence Hierarchy
Frequently Asked Questions
What are the best migraine prevention drugs available now?
Anti-CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) and the oral CGRP blocker atogepant are the newest and most targeted options, reducing migraine days by 1-4 per month with good tolerability.
Will these drugs work if other migraine medications didn't?
Yes — a major advantage of anti-CGRP drugs is that they remain effective in patients who didn't respond to traditional preventive medications like beta-blockers, topiramate, or amitriptyline.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15109APA
Diener, Hans Christoph; Grans, Julia; Reuter, Uwe. (2026). Drugs for Migraine Prophylaxis.. Deutsches Arzteblatt international. https://doi.org/10.3238/arztebl.m2025.0234
MLA
Diener, Hans Christoph, et al. "Drugs for Migraine Prophylaxis.." Deutsches Arzteblatt international, 2026. https://doi.org/10.3238/arztebl.m2025.0234
RethinkPeptides
RethinkPeptides Research Database. "Drugs for Migraine Prophylaxis." RPEP-15109. Retrieved from https://rethinkpeptides.com/research/diener-2026-drugs-for-migraine-prophylaxis
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.